Most researchers searching for CJC-1295 in Boka soon discover that local retail options are essentially nonexistent. This matters because CJC-1295 quality differs enormously across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor controls every quality variable. A properly operating CJC-1295 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide guides Boka researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Boka comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Red flags in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that omit endotoxin testing. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Boka
COA-verified · International tracking · Research grade
All use of CJC-1295 in Boka or anywhere is research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
